rs772407797
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_000264.5(PTCH1):c.297C>T(p.Gly99Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000264.5 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTCH1 | ENST00000331920.11 | c.297C>T | p.Gly99Gly | synonymous_variant | Exon 2 of 24 | 5 | NM_000264.5 | ENSP00000332353.6 | ||
PTCH1 | ENST00000437951.6 | c.294C>T | p.Gly98Gly | synonymous_variant | Exon 2 of 24 | 5 | NM_001083603.3 | ENSP00000389744.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Gorlin syndrome Pathogenic:1
In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with clinical features of basal cell nevus syndrome (Invitae, external communication). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 409192). This variant is not present in population databases (ExAC no frequency). This sequence change affects codon 99 of the PTCH1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the PTCH1 protein. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.297C>T pathogenic mutation (also known as p.G99G), located in coding exon 2 of the PTCH1 gene, results from a C to T substitution at nucleotide position 297. This nucleotide substitution does not change the glycine at codon 99.This mutation has been determined to be the result of a de novo mutation in an individual diagnosed with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) (Ambry internal data). In silico splice site analysis predicts that this alteration will result in the creation or strengthening of a novel splice donor site. Internal RNA studies have demonstrated this alteration results in abnormal splicing (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at